Tower Research Capital (TRC)’s Jyong Biotech MENS Stock Holding History
Bought
Maintained
Sold
Other funds holding MENS
Tower Research Capital (TRC)'s MENS Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Jyong Biotech (MENS) stake by 226% in Q3 2026, buying an estimated $5.29K and bringing the position to 3,491 shares worth $7.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4490.
Tower Research Capital (TRC) first reported a position in MENS in Q3 2025 and has held it in 5 quarters since. The position peaked at $25.2K in Q1 2026. 17 funds tracked by Wall St. Rank hold MENS as of Q3 2026.
- Tower Research Capital (TRC) held 3,491 shares of Jyong Biotech worth $7.16K as of Q3 2026.
- Tower Research Capital (TRC) bought 2,421 Jyong Biotech shares in Q3 2026, an estimated $5.29K.
- Jyong Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4490 holding.
- Tower Research Capital (TRC) first reported a position in Jyong Biotech in Q3 2025 and has held it in 5 quarters since.
- Tower Research Capital (TRC)'s Jyong Biotech position peaked at $25.2K in Q1 2026.
- 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.